Basal cell carcinoma (BCC) is the most common skin cancer. It generally has an indolent course with low rates of metastasis and mortality. However, BCC is locally invasive and can cause significant morbidity due to destructive local spread. We report our experience with a patient who was referred to our skin cancer unit due to a previously neglected lesion on the parietal region of the scalp, which had developed for 7 years. The patient was prescribed vismodegib on the basis that surgery could cause excessive functional and aesthetic damage. The patient had an objective partial response after 20 months of treatment. He was then submitted to radical skin excision, leaving a large defect that was reconstructed using a free latissimus dorsi muscle flap. The patient recovered well, and at the 1-year follow-up there were no signs of local recurrence.
Our case demonstrates the value of vismodegib treatment prior to surgery in a locally advanced, high-risk scalp BCC and highlights the importance of an individualized and specialized approach with these patients, within a multidisciplinary team.
SekulicA, MigdenMR, LewisK, et al.Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC.
J Am Acad Dermatol. 2015;72(6):1021-6.
AllyMS, AasiS, WysongA, et al.An investigator-initiated open-label clinical trial of vismodegib as a neoadjuvant to surgery for high-risk basal cell carcinoma.
J Am Acad Dermatol. 2014;71(5):904-11.
KwonGP, AllyMS, Bailey-HealyI, et al. Update to an open-label clinical trial of vismodegib as neoadjuvant before surgery for high-risk basal cell carcinoma (BCC).
ChangAL, AtwoodSX, TartarDM, OroAE. Surgical excision after neoadjuvant therapy with vismodegib for a locally advanced basal cell carcinoma and resistant basal carcinomas in Gorlin syndrome.
SagivO, NagarajanP, FerrarottoR, et al. Ocular preservation with neoadjuvant vismodegib in patients with locally advanced periocular basal cell carcinoma.
Neoadjuvant Vismodegib in Patients with Large and/or Recurrent Resectable Basal Cell Carcinoma. Bethesda: U.S. National Library of Medicine; 2017 [cited 2019 Jan 15]. Available from: https://ClinicalTrials.gov/show/NCT03035188.
ClinicalTrials.gov [Internet].
A study of Vismodegib with surgery in participants with previously untreated Basal Cell Carcinoma. Bethesda: U.S. National Library of Medicine; 2013 [cited 2019 Jan 15]. Available from: https://ClinicalTrials.gov/show/NCT01898598.
ClinicalTrials.gov [Internet].
Vismodegib in treating patients with Basal Cell Carcinoma (BCC). Bethesda: U.S. National Library of Medicine; 2012 [cited 2019 Jan 15]. Available from: https://ClinicalTrials.gov/show/NCT01631331.
ClinicalTrials.gov [Internet].
Vismodegib for treatment of Basal Cell Carcinoma. Bethesda: U.S. National Library of Medicine; 2012 [cited 2019 Jan 15]. Available from: https://ClinicalTrials.gov/show/NCT01543581.
ClinicalTrials.gov [Internet].
Study evaluating the interest of Vismodegib as neo-adjuvant treatment of basal cell carcinoma (BCC). Bethesda: U.S. National Library of Medicine; 2016 [cited 2019 Jan 15]. Available from: https://ClinicalTrials.gov/show/NCT02667574.
MortierL, BertrandN, Basset-SeguinN, et al.Vismodegib in neoadjuvant treatment of locally advanced basal cell carcinoma: First results of a multicenter, open-label, phase 2 trial (VISMONEO study).
Journal of Clinical Oncolog. 2018;36(15Suppl):9509-9509
Basset-SeguinN, HauschildA, GrobJJ, et al. vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial.
Facebook
Google+
Twitter
LinkedIn
Mendeley
StumbleUpon
CiteULike
Reddit
Email